Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

361.18 -3.06 (-0.84%)
Streaming Delayed Price Updated: 9:50 AM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years ↗
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 Today ↗
 
Via Benzinga
News headline image
Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results ↗
Krystal Biotech, Inc. (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday. 
Via Benzinga
News headline image
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
Krystal Biotech Inc. (NASDAQ: KRYS) is a Leading Gainer in 2/26 Morning Trading
Via Investor Brand Network
News headline image
Earnings Scheduled For February 26, 2024 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
News headline image
A Preview Of Krystal Biotech's Earnings ↗
 
Via Benzinga
News headline image
AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Expert Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
This Stock Has Quadrupled in 5 Years. Can It Do It Again? ↗
Have investors already missed the boat with this stock? 
Via The Motley Fool
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
A Preview Of Krystal Biotech's Earnings ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Krystal Biotech ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Krystal Biotech ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗
 
Via Benzinga
News headline image
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
News headline image
Analyst Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
Expert Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
What Will AbbVie Buy Next? ↗
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8
Via Investor Brand Network
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2023 ↗
 
Via Benzinga
News headline image
Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M ↗
Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)  
Via Benzinga
News headline image
3 Biotech Stocks to Buy Before the Breakout ↗
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023 ↗
 
Via Benzinga
News headline image
2 Soaring Stocks With More Upside Potential ↗
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
News headline image
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
News headline image
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.